EMD Seminar Series: Louis Bont - "All you did not yet learn about RSV immunizations"
Respiratory Syncytial Virus (RSV) is a leading cause of acute lower respiratory tract infections in infants and young children globally, with significant morbidity and mortality. Most infants with severe disease were healthy term infants until infected with RSV. Each year, RSV accounts for an estimated 33 million cases, over 3 million hospitalizations, and more than 100,000 deaths in children under five—predominantly in low- and middle-income countries (LMICs). Following decades of research, effective preventive tools have only recently become available, marking a turning point in RSV control.
This lecture aims to provide an up-to-date overview of the evolving RSV prevention landscape. The scientific breakthrough leading to the development of RSV immunization was the discovery that there are 2 conformation of the RSV F protein: the pre-fusion and post-fusion. Two major strategies now available for infant protection will be discussed: long-acting monoclonal antibodies (mAbs), such as nirsevimab, and a stabilized preF-based maternal RSV vaccination during pregnancy. These interventions offer complementary approaches to bridging the vulnerable early months of life when infants are at the highest risk of severe disease. Recent approval of clesrovimab, another mAb, directed against a different epitope of preF (site IV) will be discussed.
The lecture will explore the clinical efficacy and safety profiles of these tools based on data from pivotal trials and recent real-world implementation. By reviewing real-world data from early adopters, we aim to translate emerging evidence into actionable insights for clinical practice. We will also address outstanding questions around seasonality, cost-effectiveness, effects on the burden by other pathogens and prioritization, particularly in resource-limited settings.
This lecture will empower clinicians, patients and public health officials to understand and advocate for the most effective strategies to reduce the global burden of RSV and protect all babies in the world.
YSPH values inclusion and access for all participants
If you have questions about accessibility or would like to request an accommodation, please contact Christina Ciarleglio at christina.ciarleglio@yale.edu